The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries
- PMID: 22379167
- PMCID: PMC9487475
- DOI: 10.1183/09059180.00000512
The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries
Conflict of interest statement
M. Humbert has relationships with drug companies including Actelion, AstraZeneca, Bayer, BMS, GSK, Merck, Novartis, Nycomed, Pfizer, Stallergènes, TEVA and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
Figures
References
-
- McGoon MD, Krichman A, Farber HW, et al. . Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc 2008; 83: 923–931. - PubMed
-
- Badesch DB, Raskob GE, Elliott CG, et al. . Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376–387. - PubMed
-
- Benza RL, Miller DP, Gomberg-Maitland M, et al. . Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164–172. - PubMed
-
- Rich S, Dantzker DR, Ayres SM, et al. . Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–223. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical